...
首页> 外文期刊>Journal of Clinical Microbiology >Detection of Resistance to Beta-Lactamase Inhibitors in Strains with CTX-M Beta-Lactamases: a Multicenter External Proficiency Study Using a Well-Defined Collection of Escherichia coli Strains
【24h】

Detection of Resistance to Beta-Lactamase Inhibitors in Strains with CTX-M Beta-Lactamases: a Multicenter External Proficiency Study Using a Well-Defined Collection of Escherichia coli Strains

机译:使用CTX-Mβ-内酰胺酶检测菌株对β-内酰胺酶抑制剂的抗性:使用定义明确的大肠杆菌菌株集合进行的多中心外部能力研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Under the auspices of the Spanish Society for Infectious Diseases and Clinical Microbiology Quality Control program, 14 Escherichia coli strains masked as blood culture isolates were sent to 68 clinical microbiology laboratories for antimicrobial susceptibility testing to β-lactam antibiotics. This collection included three control strains (E. coli ATCC 25922, an IRT-2 producer, and a CMY-2 producer), six isogenic strains with or without the OmpF porin and expressing CTX-M β-lactamases (CTX-M-1, CTX-M-15, and CTX-M-14), one strain carrying a double mechanism for β-lactam resistance (i.e., carrying CTX-M-15 and OXA-1 enzymes), and four strains carrying CTX-M variants with different levels of resistance to β-lactams and β-lactam–β-lactamase inhibitor (BLBLI) combinations. The main objective of the study was to ascertain how these variants with reduced susceptibilities to BLBLIs are identified in clinical microbiology laboratories. CTX-M variants with high resistance to BLBLIs were mainly identified as inhibitor-resistant TEM (IRT) enzymes (68.0%); however, isogenic CTX-M mutant strains with reduced susceptibilities to BLBLIs and cephalosporins were mainly associated with extended-spectrum β-lactamase production alone (51 to 80%) or in combination with other mechanisms (14 to 31%). Concerning all β-lactams tested, the overall interpretative discrepancy rate was 11.5%, of which 38.1% were the consequence of postreading changes in the clinical categories when a resistance mechanism was inferred. Therefore, failure to recognize these complex phenotypes might contribute to an explanation of their apparent absence in the clinical setting and might lead to inadequate drug treatment selection. A proposal for improving recognition is to adhere strictly to the current CLSI or EUCAST guidelines for detecting reduced susceptibility to BLBLI combinations, without any interpretative modification.
机译:在西班牙传染病学会和临床微生物学质量控制计划的主持下,将被掩盖为血培养分离物的14株大肠杆菌菌株送至68个临床微生物学实验室,对β-内酰胺类抗生素进行了药敏试验。该集合包括三个对照菌株(大肠杆菌ATCC 25922,IRT-2生产商和CMY-2生产商),六个有或没有OmpF孔蛋白并表达CTX-Mβ-内酰胺酶(CTX-M-1 ,CTX-M-15和CTX-M-14),一株具有β-内酰胺抗性双重机制的菌株(即,带有CTX-M-15和OXA-1酶)和四株带有CTX-M变体的菌株对β-内酰胺和β-内酰胺-β-内酰胺酶抑制剂(BLBLI)组合具有不同水平的耐药性。这项研究的主要目的是确定如何在临床微生物学实验室中鉴定出对BLBLIs敏感性降低的这些变体。对BLBLI具有高抗性的CTX-M变体主要被鉴定为抗抑制剂的TEM(IRT)酶(68.0%)。然而,对BLBLIs和头孢菌素敏感性降低的同基因CTX-M突变株主要与单独使用广谱β-内酰胺酶(51%至80%)或与其他机制结合(14%至31%)有关。对于所有测试的β-内酰胺类药物,总体解释差异率为11.5%,其中38.1%是由于推断耐药机制后临床类别的阅读后变化所致。因此,无法识别这些复杂的表型可能有助于解释其在临床环境中的明显缺失,并可能导致药物治疗选择不足。提高识别度的建议是严格遵守当前的CLSI或EUCAST指南,以检测对BLBLI组合的敏感性降低,而无需进行任何解释性修改。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号